News Europe European Cannabis THC Levels Have Doubled In 10 years

European Cannabis THC Levels Have Doubled In 10 years

-

Advertising

THC levels in European cannabis have more than doubled in a decade with cannabis the most widely used ‘illicit’ drug in Europe, show recent research.

The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) report shows that the THC (Tetrahydrocannabinol) concentration of ‘herbal cannabis’ doubled from 5% to 10%, from 2006 to 2016.

The report — Developments In The European Cannabis Market — provides an overview of emerging and established cannabis trends in Europe.

It says the global moves towards legalisation of recreational cannabis, and the wider adoption of cannabis as a medicine – are driving innovation.

This is leading to a surge in the development of new cannabis products, and some of these are now appearing in the European market.

The report calls for closer monitoring of the health effects of all cannabis products. EMCDDA Director Alexis Goosdeel said: “New and more potent cannabis products may have serious public health consequences for users. 

“Therefore, monitoring and understanding new trends in cannabis products available to European consumers today is important to inform the policy and regulatory debate.”

With concentrates, edibles, and CBD nutraceuticals now prevalent in Europe  the report calls for new monitoring tools and regulations. 

It says: “Having the ability to distinguish illicit cannabis products from cannabis-based medicinal products and unregulated CBD oils will be important for law enforcement in many jurisdictions.”

The report gores on to say that some 17.5 m Europeans, aged between 15–34, are estimated to have used cannabis in the last year, while one per cent of 1% of adults – aged between 15 and 64 years, use cannabis every day.

In 2017, some 155,000 people entered drug treatment in Europe for problems related to this drug, of those around 83,000 were entering treatment for the first time. 

Cannabis is now the substance most often named by new entrants to specialist drug treatment services as their main reason for contact in the 28-member states of the European Union, says the report.

Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

Amazon Listing Boosts Sales For UK CBD Firm By ‘150%’

UK company fourfivecbd has seen a 150% sales increase of its muscle rub CBD balm following its...

European Commission Apologises Over Misleading Novel Food Statements – As Crucial Dates For Europe’s Cannabis Future Revealed

THE European Commission says it has stopped all non-synthetic Novel Food CBD applications - and apologised for...

Markets: World’s Leading Drug Companies Finding A Way Into Cannabis.

THE emerging cannabis industry is moving up the agenda for the pharmaceutical industry with two significant deals...

Amazon’s UK Launch Expected Within Weeks After Successful CBD Pilot Project

AMAZON’S CBD pilot is proving a success and set to debut in the UK later this year...

Advertising

Meet The Two Cannabis Scientists Focused On Boosting Women’s Health

A PAIR of female scientists are leading the way when it comes to exploring the benefits CBD...

New UK Cannabis Fund Closes In On Its First $75m Investment

ONE of the UK’s first cannabis investment funds is being backed by two of the industry’s global...

Must read

Advertising

You might also likeRELATED
Recommended to you